Article
Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.
Drug development research - 1 Sept 2025
Gawli Chandrakant S, Nagpure Narendra R, Patil Bhatu R, Ochi Nobuaki, Takigawa Nagio, Patel Harun M
Abstract excerpt
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with "epidermal growth factor receptor (EGFR)" mutations playing a pivotal role in tumor progression and carcinogenesis. "Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)," such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.